SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. (Nasdaq: SABS) is a clinical-stage biopharmaceutical company that completed its public debut through a merger with Big Rock Partners Acquisition Corp., a blank-check company sponsored by Big Rock Partners LLC, which closed in October 2021. The company, headquartered in Sioux Falls, South Dakota, develops human polyclonal antibodies using its proprietary transchromosomic bovine platform, placing it squarely in the immunology and biologics segment of the biotechnology sector. On May 4, 2026, the company filed an 8-K current report with the SEC under accession number 0001193125-26-204125, continuing its public disclosure obligations as a Nasdaq-listed registrant. For complete filing history, pipeline status, and ongoing corporate event data on SABS and hundreds of other SPAC-derived companies, visit SpacDesk and sign up for full access.